{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-027121","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2022-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.980285+00:00","generated_at":"2026-06-23T06:51:09.328964+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Anixa Biosciences reports favorable safety and stable tumor lesions in first patient of CAR-T trial","bullets":["First patient treated in chimeric endocrine receptor T-cell (CAR-T) clinical trial shows favorable safety signals.","Imaging at one month post-treatment indicates tumor lesions are stable and not growing.","Patient appears to be doing well and will continue to be monitored; enrollment continues.","Data presented by inventor Dr. Jose Conejo-Garcia at AACR/Rivkin Ovarian Cancer Symposium."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-027121","json":"https://secwatch.observer/filing/0001493152-22-027121.json","markdown":"https://secwatch.observer/filing/0001493152-22-027121.md","text":"https://secwatch.observer/filing/0001493152-22-027121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315222027121/0001493152-22-027121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315222027121/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:51:09.328964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}